Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 4/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2256955 | 0.90 | APP (0.46) | MERTKAPPMAPTMAPK1KMT2A | |
| SCHEMBL2255107 | 0.85 | APP (0.63) | APPMAPTKMT2AALDH1A1LMNA | |
| SCHEMBL5557336 | 0.85 | MERTK (0.48) | MERTKAPPMAPTMAPK1KMT2A | |
| SCHEMBL2258636 | 0.84 | ADORA3 (0.46) | APPMAPTMAPK1KMT2ANPC1 | |
| SCHEMBL2258988 | 0.84 | MERTK (0.39) | MERTKAPPMAPTMAPK1KMT2A | |
| SCHEMBL3118700 | 0.83 | NUDT1 (0.40) | MERTKAPPKMT2AMEN1ALDH1A1 | |
| SCHEMBL3118890 | 0.83 | ADORA2A (0.45) | APPMAPTMAPK1KMT2ANPC1 | |
| SCHEMBL2256520 | 0.83 | ADORA2A (0.58) | APPMAPTKMT2AALDH1A1LMNA | |
| SCHEMBL92684 | 0.82 | ADORA2A (0.42) | APPMAPTKMT2ANPC1RAB9A | |
| SCHEMBL2256494 | 0.82 | L3MBTL1 (0.47) | MERTKAPPMAPTKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258145-B2 | Method of treating brain cancer | MYREXIS, INC. (US) | 2012-09-04 | — | — | US | claimed |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | Myriad Pharmaceuticals, Incorporated (US) | 2010-03-18 | — | — | US | claimed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20080051398-A1 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2008-02-28 | — | — | US | claimed |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| EP-1833511-A2 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | claimed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | claimed |
| JP-2007524637-A | — | — | 2007-08-30 | — | — | JP | claimed |
| WO-2006074187-A2 | METHOD OF TREATING BRAIN CANCER | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | claimed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | claimed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | MERTK 1675/4885APP 3339/4885MAPT 4163/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | MERTK 2283/4885APP 2989/4885MAPT 4241/4885 |
| US-20100069383-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | MERTK 1812/4885APP 3261/4885MAPT 4082/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | MERTK 1675/4885APP 3339/4885MAPT 4163/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | MERTK 1675/4885APP 3339/4885MAPT 4163/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | MERTK 1675/4885APP 3339/4885MAPT 4163/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | MERTK 1675/4885APP 3339/4885MAPT 4163/4885 |
| US-20070249601-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | MERTK 1675/4885APP 3339/4885MAPT 4163/4885 |
| US-20080051398-A1 | METHOD OF TREATING BRAIN CANCER | CASP3, CASP7, BAD | MERTK 3755/4885APP 4555/4885MAPT 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.